Brief: Orgenesis And Kurve Therapeutics Announce Pre-Clinical Study Results For A Cell-Based Oncolytic Virus Bearing Product
20/12/2022 13:02
Dec 20 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS AND KURVE THERAPEUTICS ANNOUNCE PRE-CLINICAL
STUDY
RESULTS FOR A CELL-BASED ONCOLYTIC VIRUS BEARING PRODUCT
DEMONSTRATING OVER 50% REDUCTION IN A MURINE GLIOBLASTOMA MODEL
Source text for Eikon: ID:nGNX1Vjs2y
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules